Cargando…

Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

OBJECTIVES: To evaluate systemic lupus erythematosus (SLE) flares following hydroxychloroquine (HCQ) reduction or discontinuation versus HCQ maintenance. METHODS: We analysed prospective data from the Systemic Lupus International Collaborating Clinics (SLICC) cohort, enrolled from 33 sites within 15...

Descripción completa

Detalles Bibliográficos
Autores principales:	Almeida-Brasil, Celline C, Hanly, John G, Urowitz, Murray, Clarke, Ann Elaine, Ruiz-Irastorza, Guillermo, Gordon, Caroline, Ramsey-Goldman, Rosalind, Petri, Michelle, Ginzler, Ellen M, Wallace, D J, Bae, Sang-Cheol, Romero-Diaz, Juanita, Dooley, Mary Anne, Peschken, Christine, Isenberg, David, Rahman, Anisur, Manzi, Susan, Jacobsen, Søren, Lim, Sam, van Vollenhoven, Ronald F, Nived, Ola, Jönsen, Andreas, Kamen, Diane L, Aranow, Cynthia, Sanchez-Guerrero, Jorge, Gladman, Dafna D, Fortin, Paul R, Alarcón, Graciela S, Merrill, Joan T, Kalunian, Kenneth, Ramos-Casals, Manuel, Steinsson, Kristján, Zoma, Asad, Askanase, Anca, Khamashta, Munther A, Bruce, Ian N, Inanc, Murat, Abrahamowicz, Michal, Bernatsky, Sasha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Systemic Lupus Erythematosus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862090/ https://www.ncbi.nlm.nih.gov/pubmed/34911705 http://dx.doi.org/10.1136/annrheumdis-2021-221295

Ejemplares similares

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients
por: Isenberg, D., et al.
Publicado: (2017)

Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
por: Hanly, John G., et al.
Publicado: (2019)

Predictors of Unsuccessful Hydroxychloroquine Tapering and Discontinuation: Can We Personalize Decision‐Making in Systemic Lupus Erythematosus Treatment?
por: Almeida‐Brasil, Celline C., et al.
Publicado: (2022)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
por: Bruce, Ian N, et al.
Publicado: (2015)

A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis
por: Rovin, Brad H., et al.
Publicado: (2016)

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus
por: van Vollenhoven, Ronald F, et al.
Publicado: (2022)

Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine
por: Almeida-Brasil, Celline C, et al.
Publicado: (2022)

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
por: Atisha‐Fregoso, Yemil, et al.
Publicado: (2020)

Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
por: Petri, Michelle, et al.
Publicado: (2023)

Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis
por: Urowitz, Murray B, et al.
Publicado: (2019)

Long‐Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy‐Six–Week Phase III Parent Study in the United States
por: Furie, Richard A., et al.
Publicado: (2018)

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
por: Bruce, Ian N, et al.
Publicado: (2022)

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
por: Vital, Edward M, et al.
Publicado: (2022)

Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
por: Petri, Michelle, et al.
Publicado: (2013)

What Does It Mean to Be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials
por: Furie, Richard, et al.
Publicado: (2021)

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus
por: Ramsey‐Goldman, Rosalind, et al.
Publicado: (2019)

Cumulative Corticosteroid Dose Over Fifty‐Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials
por: van Vollenhoven, Ronald F., et al.
Publicado: (2016)

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
por: Kalunian, Kenneth C., et al.
Publicado: (2022)

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus
por: Wallace, Daniel J., et al.
Publicado: (2019)

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
por: Doria, A., et al.
Publicado: (2018)

Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus
por: Ginzler, Ellen, et al.
Publicado: (2021)

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
por: Morand, Eric, et al.
Publicado: (2022)

Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus
por: McElhone, Kathleen, et al.
Publicado: (2016)

Interaction between the STAT4 rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus
por: Reid, Sarah, et al.
Publicado: (2021)

High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus
por: Reid, Sarah, et al.
Publicado: (2020)

Suppression of Serum Interferon‐γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus
por: Cesaroni, Matteo, et al.
Publicado: (2021)

Novel Assays of Thrombogenic Pathogenicity in the Antiphospholipid Syndrome Based on the Detection of Molecular Oxidative Modification of the Major Autoantigen β(2)-Glycoprotein I
por: Ioannou, Yiannis, et al.
Publicado: (2011)

Biological impact of iberdomide in patients with active systemic lupus erythematosus
por: Lipsky, Peter E, et al.
Publicado: (2022)

Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort
por: Mendel, Arielle, et al.
Publicado: (2019)

Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus
por: Odqvist, Lina, et al.
Publicado: (2019)

Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing
por: Sandling, Johanna K, et al.
Publicado: (2021)

Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort
por: Urowitz, M B, et al.
Publicado: (2016)

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
por: Clowse, Megan E. B., et al.
Publicado: (2017)

Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
por: Parker, Ben, et al.
Publicado: (2013)

Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study
por: Ferreira, Isabel, et al.
Publicado: (2017)

Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia
por: Lewis, Myles J, et al.
Publicado: (2012)

Lack of Effect of a Single Injection of Human C-Reactive Protein on Murine Lupus or Nephrotoxic Nephritis
por: Carlucci, Francesco, et al.
Publicado: (2010)

Oxidative Stress, T Cell DNA Methylation, and Lupus
por: Li, YePeng, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jabmi2lvdmminb85gevh61rmdg